Galectin Therapeutics Inc. Aktie News

Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis. GALT reported a narrower Q3 loss due to lower R&D and operating expenses post-trial, with a cash runway through mid-2026 after securing a $10M credit line. Belapectin demonstrated reductions in liver stiffness, fibrogenesis, and new varices, especially in high-...

Galectin Therapeutics targets MASH cirrhosis with belapectin, addressing a highly unmet need with clear mechanistic rationale and promising clinical data. GALT's NAVIGATE trial showed belapectin's 2 mg/kg dose significantly reduced disease progression and varices in high-risk patients, with consistent biomarker improvements. Despite a constrained cash runway through mid-2026 and dose-response q...

NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025.

NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York, NY.